Chemical Structure (Duloxetine 01)
Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 71335-0392
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71335-0392). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Duloxetine 02)
The text describes a graph showing the proportion of patients with relapse over time (in days) from randomization. The graph compares the results between two treatments; a placebo and a medication called Duloxetine delayed-release. The graph displays the proportion of patients that experienced relapse, with higher numbers indicating a higher incidence of relapse. The x-axis shows the time period from randomization to relapse (in days), and the y-axis indicates the proportion of patients with relapse.*
Figure 2 (Duloxetine 03)
Figure 3 (Duloxetine 04)
Figure 4 (Duloxetine 05)
Figure 5 (Duloxetine 06)
Figure 6 (Duloxetine 07)
Figure 8 (Duloxetine 08)
This is a chart showing the percentage of patients who improved with a placebo and Duloxetine (60/120 mg taken once daily) for pain relief. The chart shows that 80% of patients improved with Duloxetine while 70% improved with a placebo. The percentages are shown on the y-axis while the percentage improvement in pain from baseline is shown on the x-axis.*
Figure 9 (Duloxetine 09)
This is a graph that shows the percentage of patients who experienced improvement in pain from baseline when taking either a placebo or a daily dose of 60mg of DUL. The x-axis shows the percentage improvement while the y-axis shows the number of patients. The graph indicates that there is a higher percentage of patients who experienced improvement in pain when taking the DUL medication compared to the placebo. However, there is not enough information provided to determine the exact percentage of patients who experienced improvement in pain.*
Figure 10 (Duloxetine 10)
This is a chart showing the percentage of patients who experienced improvement in pain from baseline while taking a drug named DULB0/120 mg once daily, compared to a placebo. The X-axis represents the percent improvement in pain from baseline, while the Y-axis represents different values ranging from 0 to 100.*
Label (Lbl713350392)
This is a medication package for a 30mg capsule of an unknown drug. It is compared to Cymbalta 30mg capsules. The package was put together by Bryant Ranck Prepack, and contains 30 capsules with an expiration date of MM/YY. The NDC number is 7133503921. It warns that the medication may cause drowsiness and should be stored at temperatures between 20°C-25°C (68°F-77°F). However, the name of the medication is not available in the text.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
